Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.

Literature DB >> 8519650

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.

C Missale¹, M Losa, F Boroni, M Giovanelli, A Balsari, P F Spano.

Abstract

Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 8519650 PMCID： PMC2034102 DOI： 10.1038/bjc.1995.520

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

8 in total

Review 1. Management of prolactinomas.

Authors: D Cunnah; M Besser
Journal: Clin Endocrinol (Oxf) Date: 1991-03 Impact factor: 3.478

2. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.

Authors: J A Schlechte; B M Sherman; F K Chapler; J VanGilder
Journal: J Clin Endocrinol Metab Date: 1986-06 Impact factor: 5.958

3. Giant invasive prolactinoma: a case report and review of nine further cases.

Authors: J R Davis; M C Sheppard; D A Heath
Journal: Q J Med Date: 1990-03

4. Nerve growth factor suppresses the transforming phenotype of human prolactinomas.

Authors: C Missale; F Boroni; M Losa; M Giovanelli; A Zanellato; R Dal Toso; A Balsari; P Spano
Journal: Proc Natl Acad Sci U S A Date: 1993-09-01 Impact factor: 11.205

5. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects.

Authors: B G Petty; D R Cornblath; B T Adornato; V Chaudhry; C Flexner; M Wachsman; D Sinicropi; L E Burton; S J Peroutka
Journal: Ann Neurol Date: 1994-08 Impact factor: 10.422

6. Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype.

Authors: C Missale; F Boroni; S Sigala; A Zanellato; R Dal Toso; A Balsari; P Spano
Journal: Endocrinology Date: 1994-07 Impact factor: 4.736

7. Resistance to bromocriptine in prolactinomas.

Authors: I Pellegrini; R Rasolonjanahary; G Gunz; P Bertrand; S Delivet; C P Jedynak; C Kordon; F Peillon; P Jaquet; A Enjalbert
Journal: J Clin Endocrinol Metab Date: 1989-09 Impact factor: 5.958

Review 8. Dopamine, the dopamine D2 receptor and pituitary tumours.

Authors: D F Wood; J M Johnston; D G Johnston
Journal: Clin Endocrinol (Oxf) Date: 1991-12 Impact factor: 3.478

8 in total

9 in total

Review 1. Pharmacologic resistance in prolactinoma patients.

Authors: Mark E Molitch
Journal: Pituitary Date: 2005 Impact factor: 4.107

Review 2. Growth factors in the pathogenesis of prolactin-secreting tumors.

Authors: C Missale; P F Spano
Journal: J Endocrinol Invest Date: 1998-06 Impact factor: 4.256

3. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines.

Authors: C Missale; A Codignola; S Sigala; A Finardi; M Paez-Pereda; E Sher; P F Spano
Journal: Proc Natl Acad Sci U S A Date: 1998-04-28 Impact factor: 11.205

Review 4. Growth factors in pituitary tumors.

Authors: C Missale; C Fiorentini; A Finardi; P Spano
Journal: Pituitary Date: 1999-05 Impact factor: 4.107